Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma Journal Article


Authors: Glick, R. D.; Swendeman, S. L.; Coffey, D. C.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.; La Quaglia, M. P.
Article Title: Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma
Abstract: Inhibitors of histone deacetylase (HDAC) have been shown to have both apoptotic and differentiating effects on various tumor cells. M-carboxy- cinnamic acid bishydroxamide (CBHA) is a recently developed hybrid polar compound structurally related to hexamethylene bisacetamide. CBHA is a potent inhibitor of HDAC activity. CBHA induces cellular growth arrest and differentiation in model tumor systems. We undertook an investigation of the effects of CBHA on human neuroblastoma cell lines in vitro. When added to cultures of a panel of neuroblastoma cell lines, CBHA induced the accumulation of acetylated histones H3 and H4, consistent with the inhibition of HDAC. Concentrations of CBHA between 0.5 μM and 4 μM led to apoptosis in nine of nine neuroblastoma cell lines. Apoptosis was assessed by DNA fragmentation analysis and the appearance of a sub-G1 (< 2N ploidy) population by flow cytometric analysis. The addition of a caspase inhibitor (henzyloxycarhonyl-Val-Ala-Asp-fluoromethyl ketone) completely abrogated CBHA-induced apoptosis in three of three cell lines. The addition of cycloheximide greatly reduced CBHA-induced apoptosis, suggesting that apoptotic induction was dependent on de novo protein synthesis. In addition, CBHA induced the expression of both CD95 (APO-1/Fas) and CD95 ligand within 12 h. The effect of CBHA on human neuroblastoma cells suggests that this agent and structurally related synthetic hybrid polar compounds have therapeutic potential for the treatment of this malignancy.
Keywords: controlled study; human cell; antineoplastic agents; flow cytometry; cell division; apoptosis; enzyme inhibition; fas antigen; fas ligand; cancer cell culture; tumor cells, cultured; enzyme inhibitor; caspase inhibitor; caspases; neuroblastoma; enzyme inhibitors; membrane glycoproteins; fas ligand protein; cell nucleus; histones; histone deacetylases; dna determination; histone deacetylase; dna degradation; cinnamic acid derivative; cinnamates; dna fragmentation; cycloheximide; antigens, cd95; hexamethylenebisacetamide; humans; human; priority journal; article
Journal Title: Cancer Research
Volume: 59
Issue: 17
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 1999-09-01
Start Page: 4392
End Page: 4399
Language: English
PUBMED: 10485488
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 16 August 2016 -- Source: Scopus
Citation Impact
MSK Authors
  1. Victoria M Richon
    91 Richon
  2. Richard D Glick
    10 Glick
  3. Paul Marks
    186 Marks
  4. Richard Rifkind
    118 Rifkind